Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)

BACKGROUND: Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy. METHODS: Between September and Nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Martínez, A., Mora-Rillo, M., Ferreras, C., Guerra-García, P., Pascual-Miguel, B., Mestre-Durán, C., Borobia, A.M., Carcas, A.J., Queiruga-Parada, J., García, I., Sánchez-Zapardiel, E., Gasior, M., De Paz, R., Marcos, A., Vicario, J.L., Balas, A., Moreno, M.A., Eguizabal, C., Solano, C., Arribas, J.R., Buckley, R.de Miguel, Montejano, R., Soria, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361305/
https://www.ncbi.nlm.nih.gov/pubmed/34405140
http://dx.doi.org/10.1016/j.eclinm.2021.101086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361305/
https://www.ncbi.nlm.nih.gov/pubmed/34405140
http://dx.doi.org/10.1016/j.eclinm.2021.101086

Ejemplares similares